Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: GlaxoSmithKline Research and Development
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and Seretide 50/500mcg alone) in the treatment of subjects with COPD
The primary objective of the study is to compare the effects of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily with the individual treatments (tiotropium bromide 18mcg once da...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
A study of a new medicine, an intravenous antibiotic (GSK2251052) in adults, with complicated urinary tract infection or pyelonephritis
To evaluate the safety and tolerability of GSK2251052 in the treatment of adult subjects with lower cUTI and pyelonephritis (complicated and uncomplicated). To evaluate the clinical and microbiologic...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma
We plan to assess the amount of [18F]ML-10 that is taken up by cancer cells undergoing programmed cell death or apoptosis. We will assess this after chemotherapy treatment in patients with Non Hodgki...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD
The primary objective of this study is to evaluate the efficacy and safety of three doses of GSK573719 (125, 250, and 500 mcg once daily) compared with placebo in subjects with COPD in order to inform...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development
Update Il y a 4 ans
A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients with Alzheimer’s disease
To assess the safety and tolerability of GSK933776A after single and multiple dose intravenous administration in patients with Alzheimer’s disease
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Limited
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the Morning, and GW685698X 200mcg and 400mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma
The primary objective of this study is to evaluate the relative efficacy and safety of once daily and twice daily dosing and of morning and evening dosing of GW685698X in adolescent and adult subjects...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Limited
Update Il y a 4 ans
A study to test possible drug interactions with a new drug for treating skin cancer
PART A-To evaluate the effect of repeat doses of GSK2118436 on the single dose PK of S-warfarin in subjects with BRAF mutant solid tumors. PART B & C-To evaluate the effect of repeat oral doses of an...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Limited
Update Il y a 4 ans
A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed Chronic Lymphoc...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Ltd
Update Il y a 4 ans
A study to test two investigational drugs, dabrafenib and trametinib, for treating melanoma
To establish the superiority of dabrafenib and trametinib combination therapy over dabrafenib and trametinib placebo (dabrafenib monotherapy) with respect to progression-free survival (PFS) for subjec...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Research and Development Limited
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP)
To determine the efficacy of oral eltrombopag, when administered once daily, for 6 months duration, to previously treated adult subjects with chronic ITP
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
7
8
9
10
Next